NASDAQ:SVRA

Savara Competitors

$2.00
+0.01 (+0.50 %)
(As of 04/23/2021 12:55 PM ET)
Add
Compare
Today's Range
$1.95
Now: $2.00
$2.08
50-Day Range
$1.57
MA: $1.87
$2.33
52-Week Range
$1.00
Now: $2.00
$3.58
Volume72,126 shs
Average Volume3.74 million shs
Market Capitalization$108.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.18

Competitors

Savara (NASDAQ:SVRA) Vs. SESN, ANIP, PBYI, EOLS, MDVL, and XOMA

Should you be buying SVRA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Savara, including Sesen Bio (SESN), ANI Pharmaceuticals (ANIP), Puma Biotechnology (PBYI), Evolus (EOLS), MedAvail (MDVL), and XOMA (XOMA).

Sesen Bio (NASDAQ:SESN) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Earnings and Valuation

This table compares Sesen Bio and Savara's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sesen BioN/AN/A$-107,500,000.00($0.39)-6.72
SavaraN/AN/A$-78,170,000.00$4.570.44

Sesen Bio is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Sesen Bio and Savara, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sesen Bio00203.00
Savara00403.00

Sesen Bio presently has a consensus price target of $7.50, indicating a potential upside of 186.26%. Savara has a consensus price target of $4.6667, indicating a potential upside of 129.89%. Given Sesen Bio's higher probable upside, equities analysts plainly believe Sesen Bio is more favorable than Savara.

Volatility & Risk

Sesen Bio has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Insider and Institutional Ownership

17.8% of Sesen Bio shares are held by institutional investors. Comparatively, 40.7% of Savara shares are held by institutional investors. 2.0% of Sesen Bio shares are held by company insiders. Comparatively, 4.8% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Sesen Bio and Savara's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sesen BioN/AN/A-14.84%
SavaraN/A-55.13%-40.08%

Summary

Savara beats Sesen Bio on 6 of the 10 factors compared between the two stocks.

Savara (NASDAQ:SVRA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Savara and ANI Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Savara00403.00
ANI Pharmaceuticals01202.67

Savara presently has a consensus price target of $4.6667, indicating a potential upside of 129.89%. ANI Pharmaceuticals has a consensus price target of $46.00, indicating a potential upside of 34.23%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than ANI Pharmaceuticals.

Insider & Institutional Ownership

40.7% of Savara shares are held by institutional investors. Comparatively, 53.4% of ANI Pharmaceuticals shares are held by institutional investors. 4.8% of Savara shares are held by insiders. Comparatively, 24.8% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Savara and ANI Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SavaraN/AN/A$-78,170,000.00$4.570.44
ANI Pharmaceuticals$206.55 million2.05$6.09 million$4.467.68

ANI Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Savara and ANI Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SavaraN/A-55.13%-40.08%
ANI Pharmaceuticals-11.92%19.01%8.15%

Risk & Volatility

Savara has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.

Summary

ANI Pharmaceuticals beats Savara on 7 of the 13 factors compared between the two stocks.

Savara (NASDAQ:SVRA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Savara and Puma Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SavaraN/AN/A$-78,170,000.00$4.570.44
Puma Biotechnology$272.30 million1.51$-75,600,000.00($1.95)-5.25

Puma Biotechnology has higher revenue and earnings than Savara. Puma Biotechnology is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

40.7% of Savara shares are owned by institutional investors. Comparatively, 87.9% of Puma Biotechnology shares are owned by institutional investors. 4.8% of Savara shares are owned by insiders. Comparatively, 21.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Savara and Puma Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SavaraN/A-55.13%-40.08%
Puma Biotechnology-23.86%-451.50%-22.80%

Analyst Ratings

This is a summary of recent ratings for Savara and Puma Biotechnology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Savara00403.00
Puma Biotechnology14102.00

Savara currently has a consensus target price of $4.6667, suggesting a potential upside of 129.89%. Puma Biotechnology has a consensus target price of $12.50, suggesting a potential upside of 22.07%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Puma Biotechnology.

Risk & Volatility

Savara has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Summary

Savara beats Puma Biotechnology on 7 of the 13 factors compared between the two stocks.

Evolus (NASDAQ:EOLS) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Evolus and Savara's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolus-120.63%-121.11%-30.91%
SavaraN/A-55.13%-40.08%

Earnings & Valuation

This table compares Evolus and Savara's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolus$34.92 million11.95$-90,030,000.00($3.19)-2.99
SavaraN/AN/A$-78,170,000.00$4.570.44

Savara has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

21.7% of Evolus shares are held by institutional investors. Comparatively, 40.7% of Savara shares are held by institutional investors. 10.1% of Evolus shares are held by company insiders. Comparatively, 4.8% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Evolus and Savara, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolus14402.33
Savara00403.00

Evolus presently has a consensus price target of $13.8889, suggesting a potential upside of 45.59%. Savara has a consensus price target of $4.6667, suggesting a potential upside of 129.89%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Evolus.

Risk & Volatility

Evolus has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Summary

Savara beats Evolus on 8 of the 12 factors compared between the two stocks.

Savara (NASDAQ:SVRA) and MedAvail (NASDAQ:MDVL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Savara and MedAvail's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SavaraN/A-55.13%-40.08%
MedAvail-245.38%-168.39%-104.11%

Volatility and Risk

Savara has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, MedAvail has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Savara and MedAvail, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Savara00403.00
MedAvail00203.00

Savara currently has a consensus target price of $4.6667, suggesting a potential upside of 129.89%. MedAvail has a consensus target price of $20.00, suggesting a potential upside of 54.44%. Given Savara's higher probable upside, equities analysts plainly believe Savara is more favorable than MedAvail.

Earnings & Valuation

This table compares Savara and MedAvail's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SavaraN/AN/A$-78,170,000.00$4.570.44
MedAvail$1.03 million401.64$-4,260,000.00($5.52)-2.35

MedAvail has higher revenue and earnings than Savara. MedAvail is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

40.7% of Savara shares are owned by institutional investors. Comparatively, 40.2% of MedAvail shares are owned by institutional investors. 4.8% of Savara shares are owned by insiders. Comparatively, 45.3% of MedAvail shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Savara beats MedAvail on 8 of the 12 factors compared between the two stocks.

XOMA (NASDAQ:XOMA) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Valuation and Earnings

This table compares XOMA and Savara's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$18.37 million22.87$-1,980,000.00($0.23)-162.22
SavaraN/AN/A$-78,170,000.00$4.570.44

XOMA has higher revenue and earnings than Savara. XOMA is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

XOMA has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Institutional and Insider Ownership

57.2% of XOMA shares are held by institutional investors. Comparatively, 40.7% of Savara shares are held by institutional investors. 9.9% of XOMA shares are held by insiders. Comparatively, 4.8% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares XOMA and Savara's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
XOMA-102.23%-28.83%-11.91%
SavaraN/A-55.13%-40.08%

Analyst Recommendations

This is a summary of current recommendations for XOMA and Savara, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
XOMA00203.00
Savara00403.00

XOMA presently has a consensus price target of $46.00, indicating a potential upside of 23.29%. Savara has a consensus price target of $4.6667, indicating a potential upside of 129.89%. Given Savara's higher possible upside, analysts clearly believe Savara is more favorable than XOMA.

Summary

XOMA beats Savara on 7 of the 12 factors compared between the two stocks.

Ad The Gold Letter
Investors Profiting Big From The "Lithium War"
Early investors saw triple digit returns since 2011... experts predict even bigger returns to come.

Savara Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sesen Bio logo
SESN
Sesen Bio
1.2$2.62+3.4%$428.55 millionN/A-5.95News Coverage
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$34.27+0.3%$420.29 million$206.55 million-17.22
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.24+1.0%$416.27 million$272.30 million-7.16
Evolus logo
EOLS
Evolus
1.5$9.54+0.3%$415.90 million$34.92 million-4.70Unusual Options Activity
News Coverage
MedAvail logo
MDVL
MedAvail
1.9$12.95+3.0%$413.69 million$1.03 million-3.17
XOMA logo
XOMA
XOMA
1.5$37.31+1.6%$413.17 million$18.37 million-33.61
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.6$8.23+0.2%$411.87 million$72.96 million-2.66Analyst Report
UroGen Pharma logo
URGN
UroGen Pharma
1.8$20.00+2.0%$409.58 million$20,000.00-3.12
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$4.43+2.9%$408.10 million$36.63 million-5.21Analyst Report
DURECT logo
DRRX
DURECT
1.4$1.78+1.1%$399.88 million$29.56 million-35.59News Coverage
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$13.51+1.0%$394.47 million$18.15 million-3.18
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$17.22+1.7%$394.27 millionN/A0.00
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.56+3.0%$392.02 million$1.98 million-3.95News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.98+0.3%$391.81 millionN/A-4.89Analyst Upgrade
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$19.90+1.8%$386.81 million$362.21 million23.98News Coverage
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.49+2.0%$384.85 million$28.91 million-5.82
Cue Biopharma logo
CUE
Cue Biopharma
1.3$12.46+0.0%$379.49 million$3.46 million-7.94
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$11.61+0.0%$379.32 millionN/A-4.03
Athersys logo
ATHX
Athersys
1.3$1.74+0.6%$376.47 million$5.63 million-4.70Analyst Upgrade
Athenex logo
ATNX
Athenex
1.6$4.09+2.0%$374.76 million$101.23 million-2.80
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.95+1.9%$374.53 million$3.89 million-4.16Gap Down
Oncorus logo
ONCR
Oncorus
1.7$14.26+1.3%$370.03 millionN/A0.00Gap Down
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.02+1.9%$369.05 million$16.54 million-3.26Analyst Upgrade
Gap Down
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.51+2.6%$367.86 million$9.48 million-0.26
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.48+0.3%$352.01 million$111.39 million24.86News Coverage
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.6$13.41+2.9%$351.09 millionN/A-10.16Gap Up
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$10.19+0.7%$345.88 million$28.95 million-14.56
BELLUS Health logo
BLU
BELLUS Health
1.7$4.39+0.2%$344.68 million$30,000.00-7.44
Homology Medicines logo
FIXX
Homology Medicines
1.6$6.70+0.3%$339.28 million$1.67 million-2.45
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$9.69+1.8%$338.69 millionN/A0.00
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.05+1.4%$333.64 millionN/A-0.29
Theratechnologies logo
THTX
Theratechnologies
1.1$3.45+3.2%$323.75 million$63.22 million-11.13
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.10+2.4%$321.52 million$6.29 million-4.08
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.46+0.9%$320.73 million$11.94 million-7.60
Immunome logo
IMNM
Immunome
1.0$30.67+3.6%$315.32 millionN/A0.00Analyst Upgrade
Gap Down
Immunic logo
IMUX
Immunic
1.8$14.66+2.0%$312.32 millionN/A-4.97Analyst Report
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$6.33+2.7%$309.26 millionN/A-5.15
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$6.29+0.8%$308.03 million$2.42 million-5.52
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.53+1.5%$307.50 millionN/A-4.82
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.27+2.4%$307.31 million$6.01 million-2.66
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.26+2.9%$297.90 million$15.98 million-1.11
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$14.25+0.2%$291.17 million$22.90 million-10.71
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.06+1.9%$289.55 millionN/A-4.29
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$9.66+3.2%$282.63 million$2.71 million-16.65Analyst Report
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$12.11+5.0%$274.64 million$1.74 million-8.41
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.59+1.1%$271.57 millionN/A-4.47Gap Down
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$3.19+4.1%$271.24 million$3.05 million-4.49News Coverage
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.22+1.2%$270.86 millionN/A-2.58
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$11.99+2.7%$270.04 millionN/A-4.54
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$5.27+0.6%$268.96 million$10.64 million-1.41
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.